Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide)

Journal of Alzheimer's Disease

Volumn 40, Issue S1, 2014, Pages

  Gozes, Illana ^a   Iram, Tal ^a   Maryanovsky, Evgenia ^a   Arviv, Carmit ^a   Rozenberg, Liora ^a   Schirer, Yulie ^a   Giladi, Eliezer ^a   Furman Assaf, Sharon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Activity dependent neuroprotective protein (ADNP); aggregation; microtubules; NAP (davunetide); neuroprotection; peptides; tau; tauopathy; tubulin

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BETA TUBULIN; DAVUNETIDE; MICROTUBULE ASSOCIATED PROTEIN 2; TAU PROTEIN; TUBULIN; NEUROPROTECTIVE AGENT; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTOTEMPORAL DEMENTIA; GENOTYPE; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSGENIC MOUSE; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; RAT; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ASTROCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FRONTOTEMPORAL DEMENTIA; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RATS; SEQUENCE ANALYSIS, PROTEIN; TAU PROTEINS; TUBULIN;

EID: 84901764370     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131664     Document Type: Article

References (87)

1. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72, 1283-1293. (Pubitemid 29085045)
2. Zamostiano R, Pinhasov A, Bassan M, Perl O, Steingart RA, Atlas R, Brenneman DE, Gozes I (1999)Afemtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: A potential neuroprotective mechanism. Neurosci Lett 264, 9-12. (Pubitemid 29195936)
3. Sigalov E, Fridkin M, Brenneman DE, Gozes I (2000) VIPRelated protection against lodoacetate toxicity in pheochromocytoma (PC12) cells:Amodel for ischemic/hypoxic injury. J Mol Neurosci 15, 147-154. (Pubitemid 32281427)
4. Dresner E, Malishkevich A, Arviv C, Leibman Barak S, Alon S, Ofir R, Gothilf Y, Gozes I (2012) Novel evolutionaryconserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem 287, 40173-40185.
5. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L (2005) NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11, 353-368.
6. Gozes I (2010) Davunetide (NAP) Pharmacology: Neuroprotection and tau. In Emerging Drugs and Targets for Alzheimer's Disease,Martinez A, ed. Royal Society of Chemistry, Cambridge, pp. 108-128.
7. Idan-Feldman A, Ostritsky R, Gozes I (2012) Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis 2012, 493670.
8. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE (2000) Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293, 1091-1098. (Pubitemid 30417880)
9. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31, 165-170. (Pubitemid 46742300)
10. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325, 146-153. (Pubitemid 351439178)
11. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I (2009) NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34, 381-388.
12. Quraishe S, Cowan CM, Mudher A (2013) NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry 18, 834-842.
13. Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, Chesselet MF (2011) A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alphasynuclein inclusions. Mol Cell Neurosci 46, 597-606.
14. Idan-Feldman A, Schirer Y, Polyzoidou E, Touloumi O, Lagoudaki R, Grigoriadis NC, Gozes I (2011) Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis 44, 327-339.
15. Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I (2013) NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport. Neurobiol Dis 56C, 79-94.
16. Jehle T, Dimitriu C, Auer S, Knoth R, Vidal-Sanz M, Gozes I, Lagreze WA (2008) The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefes Arch Clin Exp Ophthalmol 246, 1255-1263.
17. Belokopytov M, Shulman S, Dubinsky G, Gozes I, Belkin M, RosnerM(2011) Ameliorative effect ofNAP on laser-induced retinal damage. Acta Ophthalmol 89, e126-e131.
18. Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE (2002) NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 19, 167-170. (Pubitemid 35013351)
19. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I (2002) NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33, 1085-1092. (Pubitemid 34293596)
20. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E (2001) A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 296, 57-63. (Pubitemid 32015060)
21. Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I (2002) A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: Gene Atlas array analysis. J Mol Neurosci 18, 37-45. (Pubitemid 34252622)
22. Zaltzman R, Beni SM, Giladi E, Pinhasov A, Steingart RA, Romano J, Shohami E, Gozes I (2003) Injections of the neuroprotective peptideNAP to newborn mice attenuate headinjury- related dysfunction in adults. Neuroreport 14, 481-484. (Pubitemid 36337955)
23. Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, Gozes I (2009) The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem 111, 1252-1263.
24. Spong CY, Abebe DT, Gozes I, Brenneman DE, Hill JM (2001) Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 297, 774-779. (Pubitemid 32378011)
25. Chen SY, Charness ME, Wilkemeyer MF, Sulik KK (2005) Peptide-mediated protection from ethanol-induced neural tube defects. Dev Neurosci 27, 13-19. (Pubitemid 40663397)
26. Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P (2011) Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: Implications for cerebral palsy. Neuroscience 173, 156-168.
27. Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I (2006) NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther 319, 332-339. (Pubitemid 44455140)
28. Morimoto BH, de Lannoy I, Fox AW, Gozes I, Stewart AJ (2009) Davunetide: Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat. Chim Oggi 27, 16-20.
29. Gold M, Lorenzl S, Stewart AJ, Morimoto BH,Williams DR, Gozes I (2012) Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 8, 85-93.
30. Brenneman DE, Gozes I (1996) A femtomolar-acting neuroprotective peptide. J Clin Invest 97, 2299-2307. (Pubitemid 26165719)
31. Brenneman DE, Hauser J, Neale E, Rubinraut S, Fridkin M, Davidson A, Gozes I (1998) Activity-dependent neurotrophic factor: Structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther 285, 619-627. (Pubitemid 28237441)
32. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I (2004) Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 309, 1190-1197. (Pubitemid 38669709)
33. Shiryaev N, Pikman R, Giladi E, Gozes I (2011) Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: Biochemical, cellular and behavioral aspects. Curr Pharm Des 17, 2603-2612.
34. Jouroukhin Y, Ostritsky R, Gozes I (2012) D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: Reviewof discovery and treatment of tauopathy. J Mol Neurosci 48, 597-602.
35. Incerti M, Toso L, Vink J, Roberson R, Nold C, Abebe D, Spong CY (2011) Prevention of learning deficit in a Down syndrome model. Obstet Gynecol 117, 354-361.
36. Wilkemeyer MF, Chen SY, Menkari CE, Brenneman DE, Sulik KK, Charness ME (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci U S A 100, 8543-8548. (Pubitemid 36849603)
37. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I (2006) Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98, 973-984. (Pubitemid 44051296)
38. Divinski I, Mittelman L, Gozes I (2004) A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279, 28531-28538. (Pubitemid 38900136)
39. Oz S, Ivashko-Pachima Y, Gozes I (2012) The ADNP derived peptide,NAP modulates the tubulin pool: Implication for neurotrophic and neuroprotective activities. PLoS One 7, e51458.
40. Sudo H, Baas PW (2011) Strategies for diminishing kataninbased loss of microtubules in tauopathic neurodegenerative diseases. Hum Mol Genet 20, 763-778.
41. Holtser-Cochav M, Divinski I, Gozes I (2006) Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci 28, 303-307. (Pubitemid 43780323)
42. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85, 890-902. (Pubitemid 10007455)
43. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, Brenneman DE (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 257, 959-966.
44. Romijn HJ, Habets AM, Mud MT, Wolters PS (1981) Nerve outgrowth, synaptogenesis and bioelectric activity in fetal rat cerebral cortex tissue cultured in serum-free, chemically defined medium. Brain Res 254, 583-589. (Pubitemid 12175371)
45. Brooke SM, Bliss TM, Franklin LR, Sapolsky RM (1999) Quantification of neuron survival in monolayer cultures using an enzyme-linked immunosorbent assay approach, rather than by cell counting. Neurosci Lett 267, 21-24. (Pubitemid 29251613)
46. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: A view of neuroprotection and cell division. J Mol Neurosci 20, 315-322. (Pubitemid 38146988)
47. Perez M, Santa-Maria I, Tortosa E, Cuadros R, Del Valle M, Hernandez F, Moreno FJ, Avila J (2007) The role of the VQIVYK peptide in tau protein phosphorylation. J Neurochem 103, 1447-1460. (Pubitemid 350001113)
48. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E (2000) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A 97, 5129-5134. (Pubitemid 30313683)
49. Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E (1998) Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37, 10223-10230. (Pubitemid 28366378)
50. Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S (2014) NAP alpha-aminoisobutyric acid (IsoNAP). J Mol Neurosci 52, 1-9.
51. Dickey C, Kraft C, Jinwal U,Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J (2009) Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol 174, 228-238.
52. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25, 10637-10647. (Pubitemid 41681911)
53. Cohen-Armon M,Visochek L, Priel E, Ishay JS (2006)Afatal effect of hornet venom on rat-brain cortical neurons. Chem Biodivers 3, 535-543. (Pubitemid 43871410)
54. Mandel S, Gozes I (2007) Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 282, 34448-34456. (Pubitemid 350159432)
55. Nogales E, Wang HW (2006) Structural intermediates in microtubule assembly and disassembly: How and why? Curr Opin Cell Biol 18, 179-184. (Pubitemid 43375886)
56. Nogales E, Wang HW (2006) Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives. Curr Opin Struct Biol 16, 221-229.
57. Cleveland DW, Hwo SY, Kirschner MW(1977) Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol 116, 207-225. (Pubitemid 8215104)
58. Cleveland DW, Hwo SY, Kirschner MW(1977) Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol 116, 227-247. (Pubitemid 8215105)
59. Andreadis A (2005) Tau gene alternative splicing: Expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta 1739, 91-103. (Pubitemid 40018532)
60. Goedert M, Jakes R (1990) Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 9, 4225-4230. (Pubitemid 120025977)
61. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubuleassociated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526.
62. Kar S, Fan J, Smith MJ, Goedert M, Amos LA (2003) Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J 22, 70-77. (Pubitemid 36091270)
63. Gozes I, Divinski I, Piltzer I (2008) NAP and D-SAL: Neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci 9(Suppl 3), S3.
64. Zemlyak I, Manley N, Sapolsky R, Gozes L (2007) NAP protects hippocampal neurons against multiple toxins. Peptides 28, 2004-2008. (Pubitemid 47419114)
65. Bassan H, Kidron D, Bassan M, Rotstein M, Kariv N, Giladi E, Davidson A, Gozes I, Harel S (2010) The effects of vascular intrauterine growth retardation on cortical astrocytes. J Matern Fetal Neonatal Med 23, 595-600.
66. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I (2004) Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol 1, 193-199.
67. Gozes I (2007) Activity-dependent neuroprotective protein: From gene to drug candidate. Pharmacol Ther 114, 146-154. (Pubitemid 46578333)
68. Fuentealba RA, Marasa J, Diamond MI, Piwnica-Worms D, Weihl CC (2012) An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet 21, 664-680.
69. Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, Gozes I (2003) The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 24, 1413-1423. (Pubitemid 38045549)
70. Gozes I, Littauer UZ (1978) Tubulin microheterogeneity increases with rat brain maturation. Nature 276, 411-413. (Pubitemid 9096476)
71. Gozes I, Sweadner KJ (1981) Multiple tubulin forms are expressed by a single neurone. Nature 294, 477-480.
72. Guo J, Walss-Bass C, Luduena RF (2010) The beta isotypes of tubulin in neuronal differentiation. Cytoskeleton (Hoboken) 67, 431-441.
73. Katsetos CD, Herman MM, Mork SJ (2003) Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 55, 77-96. (Pubitemid 36627260)
74. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L (1994) Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A 91, 11358-11362. (Pubitemid 24356343)
75. Jiang YQ, Oblinger MM (1992) Differential regulation of beta III and other tubulin genes during peripheral and central neuron development. J Cell Sci 103(Pt 3), 643-651. (Pubitemid 23023235)
76. Boutte AM, Woltjer RL, Zimmerman LJ, Stamer SL, Montine KS, Manno MV, Cimino PJ, Liebler DC, Montine TJ (2006) Selectively increased oxidative modifications mapped to detergent-insoluble forms of Abeta and beta-III tubulin in Alzheimer's disease. FASEB J 20, 1473-1483. (Pubitemid 44943855)
77. Khan IA, Luduena RF (2003) Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Invest New Drugs 21, 3-13. (Pubitemid 36628480)
78. Modig C, Olsson PE, Barasoain I, de Ines C, Andreu JM, Roach MC, Luduena RF, Wallin M (1999) Identification of betaIII- and betaIV-tubulin isotypes in cold-adapted microtubules from Atlantic cod (Gadus morhua): Antibody mapping and cDNA sequencing. Cell Motil Cytoskeleton 42, 315-330. (Pubitemid 29169853)
79. Kanakkanthara A, Northcote PT, Miller JH (2012) betaIItubulin and betaIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Mol Cancer Ther 11, 393-404.
80. Vent J,Wyatt TA, Smith DD, Banerjee A, Luduena RF, Sisson JH, Hallworth R (2005) Direct involvement of the isotypespecific C-terminus of beta tubulin in ciliary beating. J Cell Sci 118, 4333-4341. (Pubitemid 41556332)
81. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I (2003) Activity-dependent neuroprotective protein: A novel gene essential for brain formation. Brain Res Dev Brain Res 144, 83-90. (Pubitemid 36897699)
82. Mandel S, Rechavi G, Gozes I (2007) Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 303, 814-824. (Pubitemid 46341287)
83. Yang MH, Yang YH, Lu CY, Jong SB, Chen LJ, Lin YF, Wu SJ, Chu PY, Chung TW, Tyan YC (2012) Activity-dependent neuroprotector homeobox protein:Acandidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. J Proteomics 75, 3617-3629.
84. Mandel S, Spivak-Pohis I, Gozes I (2008) ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. JMol Neurosci 35, 127-141.
85. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I (2007) Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 323, 438-449. (Pubitemid 350005131)
86. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, Smith JD, Turner EH, Stanaway IB, Vernot B, Malig M, Baker C, Reilly B,Akey JM, Borenstein E, Rieder MJ, Nickerson DA, Bernier R, Shendure J, Eichler EE (2012) Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485, 246-250.
87. O'Roak BJ,Vives L, FuW, Egertson JD, Stanaway IB, Phelps IG, Carvill G,Kumar A, Lee C, Ankenman K, Munson J, Hiatt JB,Turner EH, Levy R, O'Day DR,KrummN, CoeBP, Martin BK, Borenstein E, Nickerson DA, Mefford HC, Doherty D, Akey JM, Bernier R, Eichler EE, Shendure J (2012) Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338, 1619-1622.